For a company that lost its chief executive and chief financial officer in rapid succession, Alexion Pharmaceuticals (ALXN) has managed to miraculously weather the storm, and its shares have shot higher as a result.
After losing about 35% last year, shares have rebounded by more than 17% so far in 2017.
Investors are clearly ready to overlook the company’s failures, in particular the botched clinical trial for its top-selling medical product, Soliris. The trial investigated complications around post-operative scenarios following kidney transplants.
